OR WAIT null SECS
SGS, a clinical contract research organization, announced it has consolidated its constituency portfolio in a single, comprehensive offering, strengthening its early phase drug development services. The service is aimed mostly at small and medium-sized biotech companies. It will be able to support companies through designing a focused strategy, and bringing compounds from the non-clinical to the clinical phase of development.
Read the full release here.